Clostridium-difficile-Infektionen: Epidemiologie, Klinik, Therapieoptionen und Prävention

Magnus Kaffarnik; Caroline Isner; Uwe Hamsen

doi:10.1055/s-0043-119894

Zentralblatt für Chirurgie - Zeitschrift für Allgemeine, Viszeral-, Thorax- und Gefäßchirurgie, Table of Contents

Zentralbl Chir 2018; 143(03): 241-249
DOI: 10.1055/s-0043-119894

Übersicht

Georg Thieme Verlag KG Stuttgart · New York

Clostridium-difficile-Infektionen: Epidemiologie, Klinik, Therapieoptionen und Prävention

Clostridium difficile Infection: Epidemiology, Clinical Presentation, Therapy and Prevention

Magnus Kaffarnik

¹Chirurgische Klinik, Charité – Universitätsmedizin Berlin, Deutschland

,

Caroline Isner

²Medizinische Klinik mit Schwerpunkt Infektiologie und Pneumologie, Charité – Universitätsmedizin Berlin, Deutschland

,

Uwe Hamsen

³Chirurgische Klinik, Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil, Bochum, Deutschland

› Author Affiliations

Abstract

Zusammenfassung

Clostridium-difficile-Infektionen (CDI) gehören zu den häufigsten Ursachen einer Diarrhö bei hospitalisierten internistischen und chirurgischen Patienten. Das klinische Bild reicht von milden Durchfällen bis hin zu einer pseudomembranösen Enterokolitis des Dick- und sehr selten auch des Dünndarms mit Ausbildung eines toxischen Megakolons. Auch rezidivierende Infektionen sind nicht selten. Aufgrund der signifikanten Morbiditäts- und Mortalitätsrate der CDI steht eine frühe Diagnose der Erkrankung im Vordergrund. Es ist wichtig, die Risikofaktoren für eine CDI zu kennen. Um Komplikationen zu vermeiden, muss eine Therapie frühzeitig eingeleitet werden. Die klassische konservative Therapie ist die Gabe von Antibiotika. In Entwicklung befinden sich monoklonale Antikörper und eine Clostridium-difficile-Vakzine. Bei fulminanten, septischen Verläufen ist häufig eine operative Fokussanierung indiziert. Durch minimalinvasive Operationstechniken sollte die Möglichkeit einer frühzeitigen operativen Therapie mittels doppelläufigem Ileostoma und antibiotischen Einläufen erwogen werden. Eine neue Therapiestrategie bei Infektrezidiven ist die Stuhlübertragung. Präventions- und Kontrollmaßnahmen sind wichtig, um eine Verbreitung des Erregers zu vermeiden. Dazu gehören die Isolierung von Clostridium-difficile-Patienten, die Personalisierung von Instrumenten, die Begrenzung von Patiententransporten auf notwendige Fälle, Tragen von Einmalkitteln und -handschuhen, die strenge Einhaltung der Handhygiene und das Antibiotic Stewardship (ABS).

Abstract

Clostridium difficile infections (CDI) are common causes of diarrhoea in hospitalised medical and surgical patients. Clinical presentation ranges from mild diarrhoea to pseudomembraneous enterocolitis of the colon and sometimes the small intestines, with development of a toxic megacolon. Recurrent infections are common. Early diagnosis is necessary because of high rates of complications and mortality. Knowledge of risk factors for the development of CDI is recommended. Early initiation of therapy is recommended to avoid complications and standard therapy is antibiotics, while therapy with monoclonal antibodies and vaccination is under research and development. Fulminant septic courses indicate surgical source control. Minimally invasive surgical therapy establishing a loop ileostomy and antibiotic installation via enema has to be considered as early surgical intervention. Fecal microbiotic transplantation is a new therapeutic option for recurrent infection. Provisions for prevention and control have to be established to avoid in-hospital spread of pathogenic agents. This includes isolation of patients, personalisation of instruments, restriction of in-hospital transports, protective clothing and gloves, strict hand washing and antibiotic stewardship (ABS).

Schlüsselwörter

Clostridium difficile - toxisches Megakolon - Stuhlübertragung - Mikrobiomtransfer

Key words

Clostridium difficile - toxic megacolon - stool transplantation - microbiom transfer

Full Text

References

Literatur
1 Wiegand PN, Nathwani D, Wilcox MH. et al. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect 2012; 81: 1-14
2 Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002; 346: 334-339
3 Lo Vecchio A, Zacur GM. Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol 2012; 28: 1-9
4 Valiente E, Cairns MD, Wren BW. The Clostridium difficile PCR ribotype 027 lineage: a pathogen on the move. Clin Microbiol Infect 2014; 20: 396-404
5 Arvand M, Vollandt D, Bettge-Weller G. et al. Increased incidence of Clostridium difficile PCR ribotype 027 in Hesse, Germany, 2011 to 2013. Euro Surveill 2014; 19: pii:20732
6 Kleinkauf N, Weiss B, Jansen A. et al. Confirmed cases and report of clusters of severe infections due to Clostridium difficile PCR ribotype 027 in Germany. Euro Surveill 2007; 12: E071115.2
7 Eckburg PB, Bik EM, Bernstein CN. et al. Diversity of the human intestinal microbial flora. Science (New York, NY) 2005; 308: 1635-1638
8 Napolitano LM, Edmiston jr. CE. Clostridium difficile disease: diagnosis, pathogenesis, and treatment update. Surgery 2017;
9 Shaughnessy MK, Micielli RL, DePestel DD. et al. Evaluation of hospital room assignment and acquisition of Clostridium difficile infection. Infect Control Hosp Epidemiol 2011; 32: 201-206
10 Pruitt RN, Lacy DB. Toward a structural understanding of Clostridium difficile toxins A and B. Front Cell Infect Microbiol 2012; 2: 28
11 Jank T, Giesemann T, Aktories K. Rho-glucosylating Clostridium difficile toxins A and B: new insights into structure and function. Glycobiology 2007; 17: 15R-22R
12 Pothoulakis C. Effects of Clostridium difficile toxins on epithelial cell barrier. Ann N Y Acad Sci 2000; 915: 347-356
13 McFarland LV. Renewed interest in a difficult disease: Clostridium difficile infections – epidemiology and current treatment strategies. Curr Opin Gastroenterol 2009; 25: 24-35
14 Deshpande A, Pasupuleti V, Thota P. et al. Risk factors for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol 2015; 36: 452-460
15 Janarthanan S, Ditah I, Adler DG. et al. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012; 107: 1001-1010
16 Kwok CS, Arthur AK, Anibueze CI. et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012; 107: 1011-1019
17 Tleyjeh IM, Bin Abdulhak AA, Riaz M. et al. Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis. PLoS One 2012; 7: e50836
18 Phatharacharukul P, Thongprayoon C, Cheungpasitporn W. et al. The risks of incident and recurrent Clostridium difficile-associated diarrhea in chronic kidney disease and end-stage kidney disease patients: a systematic review and meta-analysis. Dig Dis Sci 2015; 60: 2913-2922
19 Shin JH, High KP, Warren CA. Older is not wiser, immunologically speaking: effect of aging on host response to Clostridium difficile infections. J Gerontol A Biol Sci Med Sci 2016; 71: 916-922
20 Wijarnpreecha K, Sornprom S, Thongprayoon C. et al. The risk of Clostridium difficile associated diarrhea in nasogastric tube insertion: a systematic review and meta-analysis. Dig Liver Dis 2016; 48: 468-472
21 Sartelli M, Malangoni MA, Abu-Zidan FM. et al. WSES guidelines for management of Clostridium difficile infection in surgical patients. World J Emerg Surg 2015; 10: 38
22 Brown KA, Khanafer N, Daneman N. et al. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother 2013; 57: 2326-2332
23 Deshpande A, Pasupuleti V, Thota P. et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother 2013; 68: 1951-1961
24 Aquina CT, Probst CP, Becerra AZ. et al. High variability in nosocomial Clostridium difficile infection rates across hospitals after colorectal resection. Dis Colon Rectum 2016; 59: 323-331
25 Damle RN, Cherng NB, Flahive JM. et al. Clostridium difficile infection after colorectal surgery: a rare but costly complication. J Gastrointest Surg 2014; 18: 1804-1811
26 Jaber MR, Olafsson S, Fung WL. et al. Clinical review of the management of fulminant Clostridium difficile infection. Am J Gastroenterol 2008; 103: 3195-3203
27 Vaishnavi C. Clostridium difficile infection: clinical spectrum and approach to management. Indian J Gastroenterol 2011; 30: 245-254
28 Kazanowski M, Smolarek S, Kinnarney F. et al. Clostridium difficile: epidemiology, diagnostic and therapeutic possibilities – a systematic review. Tech Coloproctol 2014; 18: 223-232
29 Welfare MR, Lalayiannis LC, Martin KE. et al. Co-morbidities as predictors of mortality in Clostridium difficile infection and derivation of the ARC predictive score. J Hosp Infect 2011; 79: 359-363
30 Hookman P, Barkin JS. Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol 2009; 15: 1554-1580
31 Adams SD, Mercer DW. Fulminant Clostridium difficile colitis. Curr Opin Crit Care 2007; 13: 450-455
32 Dallal RM, Harbrecht BG, Boujoukas AJ. et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002; 235: 363-372
33 Heinlen L, Ballard JD. Clostridium difficile infection. Am J Med Sci 2010; 340: 247-252
34 Lundeen SJ, Otterson MF, Binion DG. et al. Clostridium difficile enteritis: an early postoperative complication in inflammatory bowel disease patients after colectomy. J Gastrointest Surg 2007; 11: 138-142
35 Clayton EM, Rea MC, Shanahan F. et al. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol 2009; 104: 1162-1169
36 Turgeon DK, Novicki TJ, Quick J. et al. Six rapid tests for direct detection of Clostridium difficile and its toxins in fecal samples compared with the fibroblast cytotoxicity assay. J Clin Microbiol 2003; 41: 667-670
37 Aichinger E, Schleck CD, Harmsen WS. et al. Nonutility of repeat laboratory testing for detection of Clostridium difficile by use of PCR or enzyme immunoassay. J Clin Microbiol 2008; 46: 3795-3797
38 Cardona DM, Rand KH. Evaluation of repeat Clostridium difficile enzyme immunoassay testing. J Clin Microbiol 2008; 46: 3686-3689
39 Johal SS, Hammond J, Solomon K. et al. Clostridium difficile associated diarrhoea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy. Gut 2004; 53: 673-677
40 Ha D, Tsai CJ. Pneumatosis intestinalis in a patient with recurrent Clostridium difficile infection. BMJ Case Rep 2012;
41 Kreiss C, Forohar F, Smithline AE. et al. Pneumatosis intestinalis complicating C. difficile pseudomembranous colitis. Am J Gastroenterol 1999; 94: 2560-2561
42 Kirkpatrick ID, Greenberg HM. Evaluating the CT diagnosis of Clostridium difficile colitis: should CT guide therapy?. AJR Am J Roentgenol 2001; 176: 635-639
43 Di X, Bai N, Zhang X. et al. A meta-analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity. Braz J Infect Dis 2015; 19: 339-349
44 Louie TJ, Byrne B, Emery J. et al. Differences of the fecal microflora with Clostridium difficile therapies. Clin Infect Dis 2015; 60 (Suppl. 02) S91-S97
45 Johnson S, Louie TJ, Gerding DN. et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis 2014; 59: 345-354
46 Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database Syst Rev 2017; (03) CD004610
47 Gergely Szabo B, Kadar B, Szidonia Lenart K. et al. Use of intravenous tigecycline in patients with severe Clostridium difficile infection: a retrospective observational cohort study. Clin Microbiol Infect 2016; 22: 990-995
48 Brinda BJ, Pasikhova Y, Quilitz RE. et al. Use of tigecycline for the management of Clostridium difficile colitis in oncology patients and case series of breakthrough infections. J Hosp Infect 2017; 95: 426-432
49 Dudukgian H, Sie E, Gonzalez-Ruiz C. et al. C. difficile colitis – predictors of fatal outcome. J Gastrointest Surg 2010; 14: 315-322
50 Stewart DB, Hollenbeak CS, Wilson MZ. Is colectomy for fulminant Clostridium difficile colitis life saving? A systematic review. Colorectal Dis 2013; 15: 798-804
51 Halabi WJ, Nguyen VQ, Carmichael JC. et al. Clostridium difficile colitis in the United States: a decade of trends, outcomes, risk factors for colectomy, and mortality after colectomy. J Am Coll Surg 2013; 217: 802-812
52 Bhangu A, Nepogodiev D, Gupta A. et al. Systematic review and meta-analysis of outcomes following emergency surgery for Clostridium difficile colitis. Br J Surg 2012; 99: 1501-1513
53 Neal MD, Alverdy JC, Hall DE. et al. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg 2011; 254: 423-427
54 Surawicz CM, Brandt LJ, Binion DG. et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108: 478-498
55 Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014; 20 (Suppl. 02) S1-S26
56 Trubiano JA, Cheng AC, Korman TM. et al. Australasian Society of Infectious Diseases updated guidelines for the management of Clostridium difficile infection in adults and children in Australia and New Zealand. Intern Med J 2016; 46: 479-493
57 Hussack G, Tanha J. An update on antibody-based immunotherapies for Clostridium difficile infection. Clin Exp Gastroenterol 2016; 9: 209-224
58 Lowy I, Molrine DC, Leav BA. et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362: 197-205
59 Wilcox MH, Gerding DN, Poxton IR. et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med 2017; 376: 305-317
60 Badger VO, Ledeboer NA, Graham MB. et al. Clostridium difficile: epidemiology, pathogenesis, management, and prevention of a recalcitrant healthcare-associated pathogen. JPEN J Parenter Enteral Nutr 2012; 36: 645-662
61 Johnson S, Gerding DN. Fidaxomicin “chaser” regimen following vancomycin for patients with multiple Clostridium difficile recurrences. Clin Infect Dis 2013; 56: 309-310
62 Soriano MM, Danziger LH, Gerding DN. et al. Novel fidaxomicin treatment regimens for patients with multiple Clostridium difficile infection recurrences that are refractory to standard therapies. Open Forum Infect Dis 2014; 1: ofu069
63 Goldenberg JZ, Ma SS, Saxton JD. et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2013; (05) CD006095
64 Eiseman B, Silen W, Bascom GS. et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958; 44: 854-859
65 Zainah H, Hassan M, Shiekh-Sroujieh L. et al. Intestinal microbiota transplantation, a simple and effective treatment for severe and refractory Clostridium difficile infection. Dig Dis Sci 2015; 60: 181-185
66 Agrawal M, Aroniadis OC, Brandt LJ. et al. The long-term efficacy and safety of fecal microbiota transplant for recurrent, severe, and complicated Clostridium difficile infection in 146 elderly individuals. J Clin Gastroenterol 2016; 50: 403-407
67 Aroniadis OC, Brandt LJ, Greenberg A. et al. Long-term follow-up study of fecal microbiota transplantation for severe and/or complicated Clostridium difficile infection: a multicenter experience. J Clin Gastroenterol 2016; 50: 398-402
68 Pecere S, Sabatelli M, Fantoni M. et al. Letter: faecal microbiota transplantation in combination with fidaxomicin to treat severe complicated recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2015; 42: 1030
69 Cammarota G, Masucci L, Ianiro G. et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2015; 41: 835-843
70 Fischer M, Sipe BW, Rogers NA. et al. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Aliment Pharmacol Ther 2015; 42: 470-476
71 van Beurden YH, Nieuwdorp M, van de Berg P. et al. Current challenges in the treatment of severe Clostridium difficile infection: early treatment potential of fecal microbiota transplantation. Therap Adv Gastroenterol 2017; 10: 373-381
72 Tartari E, Abbas M, Pires D. et al. World Health Organization SAVE LIVES: Clean Your Hands global campaign – ‘Fight antibiotic resistance – itʼs in your hands’. Clin Microbiol Infect 2017; 23: 596-598 doi:10.1016/j.cmi.2017.04.021
73 Christiansen B, Bitter-Suermann D. [Joint recommendations of the Association of German Faculties (MFT) and the Commission for Hospital Hygiene and Infection Prevention (KRINKO) at the Robert Koch Institute for the education of hospital hygiene at German universities]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2011; 54: 1351-1354
74 Siegel JD, Rhinehart E, Jackson M. et al. 2007 guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control 2007; 35: S65-S164
75 Weber DJ, Rutala WA. The role of the environment in transmission of Clostridium difficile infection in healthcare facilities. Infect Control Hosp Epidemiol 2011; 32: 207-209
76 de With K, Allerberger F, Amann S. et al. Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases. Infection 2016; 44: 395-439
77 Kallen AJ, Thompson A, Ristaino P. et al. Complete restriction of fluoroquinolone use to control an outbreak of Clostridium difficile infection at a community hospital. Infect Control Hosp Epidemiol 2009; 30: 264-272
78 Talpaert MJ, Gopal Rao G, Cooper BS. et al. Impact of guidelines and enhanced antibiotic stewardship on reducing broad-spectrum antibiotic usage and its effect on incidence of Clostridium difficile infection. J Antimicrob Chemother 2011; 66: 2168-2174